Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
view full news & meetings section

Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis


Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.

https://media-www.fapvoice.com/wp-content/uploads/2016/04/10.jpg

expertly curated content related to this topic